CRISPR Stock Valuation

CRSP
 Stock
  

USD 68.24  1.28  1.91%   

What is the intrinsic value of CRISPR stock? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as CRISPR Therapeutics, is its stock price multiplied by the total number of shares outstanding, calculating CRISPR Therapeutics' enterprise value requires a different approach. It uses CRISPR Therapeutics' balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
CRISPR Therapeutics Free Cash Flow is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Free Cash Flow of 457.27 Million. As of 27th of June 2022, Tangible Asset Value is likely to grow to about 3 B, while Enterprise Value is likely to drop about 4.5 B.
CRISPR Therapeutics shows a prevailing Real Value of $89.32 per share. The current price of the firm is $68.24. At this time, the firm appears to be undervalued. Our model approximates the value of CRISPR Therapeutics from reviewing the firm fundamentals such as Return On Equity of 15.39 %, profit margin of 34.04 %, and Operating Margin of 36.42 % as well as analyzing its technical indicators and Probability Of Bankruptcy. In general, we favor obtaining undervalued instruments and abandoning overvalued instruments since, in the future, asset prices and their ongoing real values will blend.
  
Refresh
CRISPR Therapeutics Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as CRISPR Therapeutics's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.

CRISPR Most Recent Valuation Data

Price Book
2.23
Enterprise Value
B
Enterprise Value Ebitda
9.08
Price Sales
5.67
Forward PE
23.36
Trailing PE
17.35
Enterprise Value Revenue
3.31
Undervalued
Today 68.24
Please note that CRISPR Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of CRISPR Therapeutics is based on 1 month time horizon. Increasing CRISPR Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for CRISPR Therapeutics AG is useful when determining the fair value of the CRISPR stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of CRISPR Therapeutics. Since CRISPR Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of CRISPR Stock. However, CRISPR Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
89.32
Real Value
94.82
Upside
Estimating the potential upside or downside of CRISPR Therapeutics AG helps investors to forecast how CRISPR stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of CRISPR Therapeutics more accurately as focusing exclusively on CRISPR Therapeutics' fundamentals will not take into account other important factors:
Earnings
Estimates (10)
LowProjected EPSHigh
4.765.005.29
Details
Hype
Prediction
LowEstimated ValueHigh
61.1666.6672.16
Details
Naive
Forecast
LowNext ValueHigh
59.1964.6970.19
Details
16 Analysts
Consensus
LowTarget PriceHigh
100.00160.69220.00
Details
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use CRISPR Therapeutics' intrinsic value based on its ongoing forecasts of CRISPR Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against CRISPR Therapeutics' closest peers. When choosing an evaluation method for CRISPR Therapeutics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.

CRISPR Valuation Drivers Correlation

Many accounts on the financial statements of CRISPR Therapeutics are highly interrelated and sometimes correlated. Consequently, when conducting CRISPR's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of CRISPR
Click cells to compare fundamentals

CRISPR Valuation Trend

Knowing CRISPR Therapeutics' actual value is paramount for traders to make sound investment determinations. CRISPR Therapeutics' real value is not only important for the investor to make better decisions but also for a more accurate overall view of CRISPR Therapeutics' financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both CRISPR Therapeutics' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.

CRISPR Market Cap

CRISPR Therapeutics AG is number one stock in market capitalization category among related companies. Market capitalization of Biotechnology industry is currently estimated at about 10.38 Billion. CRISPR Therapeutics totals roughly 5.19 Billion in market capitalization claiming about 50% of stocks in Biotechnology industry.
Capitalization  Revenue  Workforce  Valuation  Total debt

CRISPR Therapeutics Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining CRISPR Therapeutics's current stock value. Our valuation model uses many indicators to compare CRISPR Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CRISPR Therapeutics competition to find correlations between indicators driving CRISPR Therapeutics's intrinsic value. More Info.
CRISPR Therapeutics AG is number one stock in price to earning category among related companies. It is number one stock in beta category among related companies totaling about  0.12  of Beta per Price to Earning. The ratio of Price to Earning to Beta for CRISPR Therapeutics AG is roughly  8.55 . Comparative valuation analysis is a catch-all model that can be used if you cannot value CRISPR Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for CRISPR Therapeutics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CRISPR Therapeutics' earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates CRISPR Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in CRISPR Therapeutics and how it compares across the competition.

About CRISPR Therapeutics Valuation

The equity valuation mechanism determines the current worth of CRISPR Therapeutics AG on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of CRISPR Therapeutics AG. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of CRISPR Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing CRISPR Therapeutics's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of CRISPR Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of CRISPR Therapeutics. We calculate exposure to CRISPR Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to CRISPR Therapeutics's related companies.
Last ReportedProjected for 2022
Gross Profit915 M987.2 M
Profit Margin 0.47  0.51 
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. Its CRISPRCas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The companys lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patients hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics Quarterly Enterprise Value

4.12 Billion

Share

CRISPR Therapeutics Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as CRISPR Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio19.54
Revenue Growth74.40%
Enterprise Value To Ebitda9.08
Enterprise Value To Revenue3.31

CRISPR Therapeutics Current Valuation Indicators

Valuation refers to the process of determining the present value of CRISPR Therapeutics AG and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value CRISPR we look at many different elements of the entity such as CRISPR's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. CRISPR Therapeutics' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final CRISPR Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as CRISPR Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use CRISPR Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes CRISPR Therapeutics' worth.
Continue to Trending Equities. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.2 B
Quarterly Revenue Growth YOY
0.74
Return On Assets
0.0855
Return On Equity
0.15
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.